<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880865</url>
  </required_header>
  <id_info>
    <org_study_id>JEV06</org_study_id>
    <secondary_id>PHRR160822-001339</secondary_id>
    <nct_id>NCT02880865</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Institute for Tropical Medicine,</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DF/Net Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to provide evidence that co-administration of measles-mumps-rubella vaccine&#xD;
      (MMR) and live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) does not&#xD;
      adversely affect immunogenicity or safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When incorporating a new vaccine in the Expanded Programme on Immunization (EPI), it is&#xD;
      important to provide evidence that it can be introduced concurrently with other routine&#xD;
      pediatric vaccines without significantly impairing the immune response to any vaccine while&#xD;
      maximizing coverage and minimizing cost. This non-inferiority study aims to compare CD-JEV&#xD;
      and MMR responses in a population of children in a country where MMR introduction is ongoing&#xD;
      or planned. This information will help the ministries of health evaluate the addition of&#xD;
      CD-JEV into routine EPI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Actual">July 11, 2017</completion_date>
  <primary_completion_date type="Actual">May 19, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>Measles immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for measles at 56 days post-vaccination. Seropositivity was defined by a concentration of ≥ 120 mIU/mL of anti-measles neutralizing antibody titer, as measured by the plaque reduction neutralization test (PRNT) (dilution converted to concentration using the 3rd International Standard Reference serum).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rubella Seropositivity 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>Rubella immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for rubella at 56 days post-vaccination. Seropositivity was defined as antirubella immunoglobulin G (IgG) concentration of ≥ 10 IU/mL (corresponding to an optical density ratio ≥ 1.10) using a commercial IgG enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mumps Seropositivity 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>Mumps immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for mumps at 56 days post-vaccination. Seropositivity was defined as an optical density ratio ≥ 1.10 using a commercial ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Anti-measles Neutralizing Antibody Concentration at 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>Anti-measles neutralizing antibody concentration was measured by the plaque reduction neutralization test (PRNT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC for Anti-rubella IgG Antibody Concentration at 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>Anti-rubella immunoglobulin G (IgG) concentration was measured using a commercial IgG enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate for Measles 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>The seroconversion rate for measles at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination or a four-fold rise in concentration 56 days after vaccination if seropositive for measles at baseline. Seropositivity was defined by a concentration of ≥ 120 mIU/mL of anti-measles neutralizing antibody titer, as measured by the plaque reduction neutralization test (PRNT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate for Mumps 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>The seroconversion rate for mumps at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination. Seropositivity was defined as an optical density ratio ≥ 1.10, measured using a commercial ELISA. Participants with equivocal serostatus at baseline are counted as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate for Rubella 56 Days Post-vaccination</measure>
    <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
    <description>The seroconversion rate for rubella at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination or a four-fold rise in concentration 56 days after vaccination if seropositive for rubella at baseline. Seropositivity is defined as a post-vaccination concentration of ≥ 10 IU/mL measured using a commercial ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Japanese Encephalitis Seropositivity 28 Days Post-vaccination</measure>
    <time_frame>28 days after CD-JEV vaccination (Day 28 for Group 1 and Day 84 for Group 2)</time_frame>
    <description>Japanese encephalitis (JE) immunogenicity was assessed by the percentage of participants with demonstrated seropositivity 28 days after CD-JEV vaccination. Seropositivity was defined as an anti-JE serum neutralizing antibody titer of ≥ 1:10, as measured by JE PRNT-50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) for Serum Neutralizing Antibody Titer to JE Virus at 28 Days Post-vaccination</measure>
    <time_frame>28 days after CD-JEV vaccination (Day 28 for Group 1 and Day 84 for Group 2)</time_frame>
    <description>Anti-JE serum neutralizing antibody titer was measured using JE PRNT-50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immediate Reactions Within 30 Minutes of Each Vaccination</measure>
    <time_frame>30 minutes following each study vaccination</time_frame>
    <description>Participants were observed for 30 minutes after each vaccination for immediate reactions. Immediate reactions included both local (injection site) and systemic reactions. MMR vaccine was injected on left upper thigh and CD-JEV was injected on right upper thigh.&#xD;
Serious reactions were those meeting one of the following conditions:&#xD;
Death.&#xD;
Life threatening&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization.&#xD;
Resulted in a persistent or significant disability or incapacity.&#xD;
Important medical events that, based upon appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local and Systemic Reactions Within 14 Days of Each Vaccination</measure>
    <time_frame>30 minutes through 14 days following each vaccination</time_frame>
    <description>Reactogenicity post-vaccination was assessed from 30 minutes through 14 days following vaccination.&#xD;
Parents used a structured reactogenicity diary card to record the following solicited (pre-listed) local and system reactions.&#xD;
Local reactions (at injection site):&#xD;
Ecchymosis (bruising)&#xD;
Erythema (redness)&#xD;
Edema (swelling)&#xD;
Induration (hardness)&#xD;
Pain/tenderness&#xD;
Systemic reactions:&#xD;
Fever&#xD;
Rash&#xD;
Cough&#xD;
Runny nose&#xD;
Change in eating habits&#xD;
Diarrhea&#xD;
Sleepiness&#xD;
Irritability&#xD;
Unusual crying&#xD;
Vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Reactions Within 14 Days of Each Vaccination by Maximum Severity</measure>
    <time_frame>30 minutes through 14 days following each vaccination</time_frame>
    <description>Parents recorded local reactions on a diary card.&#xD;
Local ecchymosis, erythema, edema, and induration were graded as follows:&#xD;
Grade 1: ≤2.5 cm in diameter.&#xD;
Grade 2: &gt;2.5 cm in diameter with 50% of surface area of extremity segment involved.&#xD;
Grade 3: ≥50% surface area of extremity segment involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage.&#xD;
Grade 4: potentially life-threatening (e.g., abscess, exfoliative dermatitis, necrosis involving dermis or deeper tissue).&#xD;
Injection site pain/tenderness (pain without touching or tenderness when the area is touched) were graded as follows:&#xD;
Grade 1: pain/tenderness causing no or minimal limitation of use of limb. Grade 2: pain/tenderness causing greater than minimal limitation of use of limb.&#xD;
Grade 3: pain/tenderness causing inability to perform usual social and functional activities.&#xD;
Grade 4: pain/tenderness causing inability to perform basic self-care OR hospitalization indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Reactions Within 14 Days of Each Vaccination by Maximum Severity</measure>
    <time_frame>30 minutes through 14 days following each vaccination</time_frame>
    <description>Parents recorded systemic reactions on a diary card.&#xD;
Fever was recorded and graded as follows (axillary temperature):&#xD;
Grade 1: 37.5°C to 37.9°C&#xD;
Grade 2: 38.0°C to 38.4°C&#xD;
Grade 3: 38.5°C to 40.0°C&#xD;
Grade 4: &gt;40.0°C&#xD;
Rash, cough, runny nose, change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting, and any other unsolicited reaction occurring from 30 minutes through 14 days post vaccination were graded as follows:&#xD;
Grade 1: symptoms causing no or minimal interference with usual social and functional activities.&#xD;
Grade 2: symptoms causing greater than minimal interference with usual social and functional activities.&#xD;
Grade 3: symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.&#xD;
Grade 4: symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events Within 28 Days of Each Vaccination</measure>
    <time_frame>28 days following each vaccination</time_frame>
    <description>Each adverse event (AE) was assessed for relationship to vaccine by the study clinician according to the following:&#xD;
Definitely Related: An adverse event or unanticipated problem clearly related to the research procedures.&#xD;
Possibly Related: There is a reasonable possibility that the adverse event or unanticipated problem, incident, experience, or outcome may have been caused by the procedures involved in the research.&#xD;
Not Related: Any adverse event or unanticipated problem clearly not related to study procedures.&#xD;
Related adverse events includes events that were assessed as definitely or possibly related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events Throughout the Study</measure>
    <time_frame>Up to 112 days</time_frame>
    <description>A serious adverse event (SAE) was defined as an AE that met one of the following:&#xD;
Death&#xD;
Life threatening&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization&#xD;
Resulted in persistent or significant disability or incapacity&#xD;
Important medical events that, based upon appropriate medical judgment, jeopardized the participant and required medical or surgical intervention to prevent an outcomes listed above&#xD;
AEs were assessed for relationship to vaccine by the study clinician according to the following:&#xD;
Definitely Related: An AE or unanticipated problem clearly related to the research procedures.&#xD;
Possibly Related: There is a reasonable possibility that the AE or unanticipated problem, incident, experience, or outcome may have been caused by the procedures involved in the research.&#xD;
Not Related: Any AE or unanticipated problem clearly not related to study procedures.&#xD;
Related SAEs includes events that were assessed as definitely or possibly related.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">628</enrollment>
  <condition>Encephalitis, Japanese</condition>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <arm_group>
    <arm_group_label>Group 1 - MMR and CD-JEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - MMR then CD-JEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live attenuated SA 14-14-2 Japanese Encephalitis vaccine</intervention_name>
    <description>Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection</description>
    <arm_group_label>Group 1 - MMR and CD-JEV</arm_group_label>
    <arm_group_label>Group 2 - MMR then CD-JEV</arm_group_label>
    <other_name>CD-JEV</other_name>
    <other_name>CD.JEVAX®</other_name>
    <other_name>RS.JEV®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, mumps, rubella vaccine</intervention_name>
    <description>Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.</description>
    <arm_group_label>Group 1 - MMR and CD-JEV</arm_group_label>
    <arm_group_label>Group 2 - MMR then CD-JEV</arm_group_label>
    <other_name>MMR</other_name>
    <other_name>Priorix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 9 months to &lt; 10 months at the time of enrollment.&#xD;
&#xD;
          -  Residence in the study area.&#xD;
&#xD;
          -  At least one parent or guardian willing to provide written informed consent.&#xD;
&#xD;
          -  Generally healthy and free of obvious health problems as established by medical&#xD;
             history, physical examination, and clinical judgment.&#xD;
&#xD;
          -  A parent or guardian is willing to attend all planned study visits and allow home&#xD;
             visits and phone contacts, as required by the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous receipt of any measles-mumps-rubella containing vaccine.&#xD;
&#xD;
          -  Previous receipt of any Japanese encephalitis vaccine.&#xD;
&#xD;
          -  History of measles, mumps, rubella, or Japanese encephalitis infection.&#xD;
&#xD;
          -  Administration of any other vaccine within 28 days prior to administration of a study&#xD;
             vaccine or planned vaccination of any vaccine other than catch-up doses of routine EPI&#xD;
             vaccines or oral polio vaccine during the 28 days after study vaccination.&#xD;
&#xD;
          -  History of allergic disease or known hypersensitivity to any component of the study&#xD;
             vaccines and/or following administration of vaccines included in the local program of&#xD;
             immunization.&#xD;
&#xD;
          -  Use of any investigational or non-registered drug within 90 days prior to the&#xD;
             administration of study vaccines or planned administration during the study period.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within 90 days prior to&#xD;
             the administration of study vaccines or planned administration during the study&#xD;
             period.&#xD;
&#xD;
          -  Chronic administration (defined as &gt; 7 days) of immunosuppressing or other&#xD;
             immune-modifying agents within 14 days before or after vaccination (including systemic&#xD;
             corticosteroids equivalent to prednisone ≥ 0.5 mg/kg/day; topical and inhaled steroids&#xD;
             are allowed).&#xD;
&#xD;
          -  Primary or acquired immunodeficiency, including human immunodeficiency virus (HIV)&#xD;
             infection, or a family history of congenital or hereditary immunodeficiency as&#xD;
             reported by parent.&#xD;
&#xD;
          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal&#xD;
             functional abnormality, as determined by medical history or physical examination,&#xD;
             which might interfere with the study objectives.&#xD;
&#xD;
          -  Severely malnourished infants as measured by World Health Organization&#xD;
             weight-for-height tables (Z-score &lt; -3).&#xD;
&#xD;
          -  Any condition or criterion that, in the opinion of the study physician, might&#xD;
             compromise the well-being of the participant, compliance with study procedures, or&#xD;
             interpretation of the outcomes of the study.&#xD;
&#xD;
          -  Acute illness at the time of enrollment defined as the presence of a moderate or&#xD;
             severe illness with fever (axillary temperature ≥ 38.0°C) or without fever (severity&#xD;
             determined at the discretion of the study physician). Acute illness is a temporary&#xD;
             exclusion. Vaccination should be postponed at least 7 days after recovery. A visit for&#xD;
             reassessment may be scheduled 7 days or more after temporary exclusion illness is&#xD;
             resolved. Eligibility for study participation must be reassessed again at the next&#xD;
             visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>9 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Rosario Capeding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>August 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Mumps</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study team agrees that the practice of offering study results to participants in human research is fundamental to the ethical principle of respect for persons. However, the sponsor prefers to report at the aggregate level to maintain participant confidentiality and ensure results are community-based. Thus, the sponsor plans to report results at the aggregate level. The sponsor will produce a poster of the results to be placed at each health center. A community meeting may also be held to communicate the results. Aggregate results will also be posted on www.clinicaltrials.gov.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02880865/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02880865/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 2 health centers in the Philippines.</recruitment_details>
      <pre_assignment_details>Filipino children aged 9 to &lt; 10 months were randomized in a 1:1 ratio to receive measles, mumps, and rubella vaccine (MMR) and prequalified live, attenuated SA-14-4-2 Japanese encephalitis vaccine (CD-JEV) together (Group 1) or 56 days apart (Group 2). All participants received a second dose of MMR at 12 months of age.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: MMR and CD-JEV</title>
          <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
        </group>
        <group group_id="P2">
          <title>Group 2: MMR Then CD-JEV</title>
          <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received MMR Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received CD-JEV</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received MMR Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: MMR and CD-JEV</title>
          <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
        </group>
        <group group_id="B2">
          <title>Group 2: MMR Then CD-JEV</title>
          <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="314"/>
            <count group_id="B2" value="314"/>
            <count group_id="B3" value="628"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="314"/>
                    <count group_id="B3" value="628"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" lower_limit="9.0" upper_limit="10.0"/>
                    <measurement group_id="B2" value="9.2" lower_limit="9.0" upper_limit="10.0"/>
                    <measurement group_id="B3" value="9.2" lower_limit="9.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="314"/>
                    <count group_id="B3" value="628"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="301"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="314"/>
                    <count group_id="B3" value="628"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination</title>
        <description>Measles immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for measles at 56 days post-vaccination. Seropositivity was defined by a concentration of ≥ 120 mIU/mL of anti-measles neutralizing antibody titer, as measured by the plaque reduction neutralization test (PRNT) (dilution converted to concentration using the 3rd International Standard Reference serum).</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The measles per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid measles serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show measles seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination</title>
          <description>Measles immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for measles at 56 days post-vaccination. Seropositivity was defined by a concentration of ≥ 120 mIU/mL of anti-measles neutralizing antibody titer, as measured by the plaque reduction neutralization test (PRNT) (dilution converted to concentration using the 3rd International Standard Reference serum).</description>
          <population>The measles per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid measles serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show measles seropositivity at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="95.8" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.0" lower_limit="95.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypotheses evaluated the non-inferiority of the concomitant administration of MMR and CD-JEV vaccines (Group 1) to MMR and CD-JEV vaccines given 2 months apart (Group 2) in children 9 months of age at 56 days in terms of percentage of participants achieving seropositivity to measles and rubella assuming a non-inferiority margin of 10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was achieved if the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentages of participants with seropositivity between the two groups (concurrent administration minus separate administration) at 56 days post-vaccination was &gt; -10% for both measles and rubella results.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rubella Seropositivity 56 Days Post-vaccination</title>
        <description>Rubella immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for rubella at 56 days post-vaccination. Seropositivity was defined as antirubella immunoglobulin G (IgG) concentration of ≥ 10 IU/mL (corresponding to an optical density ratio ≥ 1.10) using a commercial IgG enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The rubella per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid rubella serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show rubella seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rubella Seropositivity 56 Days Post-vaccination</title>
          <description>Rubella immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for rubella at 56 days post-vaccination. Seropositivity was defined as antirubella immunoglobulin G (IgG) concentration of ≥ 10 IU/mL (corresponding to an optical density ratio ≥ 1.10) using a commercial IgG enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The rubella per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid rubella serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show rubella seropositivity at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypotheses evaluated the non-inferiority of the concomitant administration of MMR and CD-JEV vaccines (Group 1) to MMR and CD-JEV vaccines given 2 months apart (Group 2) in children 9 months of age at 56 days in terms of percentage of participants achieving seropositivity to measles and rubella assuming a non-inferiority margin of 10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was achieved if the lower limit of the two-sided 95% CI for the difference in percentages of participants with seropositivity between the two groups (concurrent administration minus separate administration) at 56 days post-vaccination was &gt; -10% for both measles and rubella results.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mumps Seropositivity 56 Days Post-vaccination</title>
        <description>Mumps immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for mumps at 56 days post-vaccination. Seropositivity was defined as an optical density ratio ≥ 1.10 using a commercial ELISA.</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The mumps per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid mumps serology results at baseline and Day 56, did not take any prohibited concomitant medications within within 28 days post-vaccination, and did not show mumps seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mumps Seropositivity 56 Days Post-vaccination</title>
          <description>Mumps immunogenicity was assessed by the percentage of participants with demonstrated seropositivity for mumps at 56 days post-vaccination. Seropositivity was defined as an optical density ratio ≥ 1.10 using a commercial ELISA.</description>
          <population>The mumps per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid mumps serology results at baseline and Day 56, did not take any prohibited concomitant medications within within 28 days post-vaccination, and did not show mumps seropositivity at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.3" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The percentage of participants with seropositivity for mumps at 56 days post-vaccination between Group 1 and Group 2 were compared using a non-inferiority test. Non-inferiority of Group 1 to Group 2 in terms of seropositivity for mumps was demonstrated if the lower limit of the two-sided 95% CI for the difference of seropositivity rates between the two groups (concurrent administration minus separate administration) at 56 days post-vaccination was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Anti-measles Neutralizing Antibody Concentration at 56 Days Post-vaccination</title>
        <description>Anti-measles neutralizing antibody concentration was measured by the plaque reduction neutralization test (PRNT).</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The measles per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid measles serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show measles seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Anti-measles Neutralizing Antibody Concentration at 56 Days Post-vaccination</title>
          <description>Anti-measles neutralizing antibody concentration was measured by the plaque reduction neutralization test (PRNT).</description>
          <population>The measles per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid measles serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show measles seropositivity at baseline.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1964.4" lower_limit="1769.3" upper_limit="2181.0"/>
                    <measurement group_id="O2" value="1866.3" lower_limit="1649.1" upper_limit="2112.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Group 1/Group 2 ratio obtained using analysis of covariance (ANCOVA) with log10-transformed antibody concentration as dependent variable and treatment group as the explanatory variable adjusted for log10-transformed baseline antibody concentration.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMC for Anti-rubella IgG Antibody Concentration at 56 Days Post-vaccination</title>
        <description>Anti-rubella immunoglobulin G (IgG) concentration was measured using a commercial IgG enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The rubella per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid rubella serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show rubella seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>GMC for Anti-rubella IgG Antibody Concentration at 56 Days Post-vaccination</title>
          <description>Anti-rubella immunoglobulin G (IgG) concentration was measured using a commercial IgG enzyme-linked immunosorbent assay (ELISA).</description>
          <population>The rubella per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid rubella serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show rubella seropositivity at baseline.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.8" lower_limit="214.4" upper_limit="248.5"/>
                    <measurement group_id="O2" value="229.8" lower_limit="210.0" upper_limit="251.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Group 1/Group 2 ratio obtained using an ANCOVA method with log 10-transformed antibody concentration as dependent variable and treatment group as explanatory variable adjusted for log 10-transformed baseline antibody concentration.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate for Measles 56 Days Post-vaccination</title>
        <description>The seroconversion rate for measles at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination or a four-fold rise in concentration 56 days after vaccination if seropositive for measles at baseline. Seropositivity was defined by a concentration of ≥ 120 mIU/mL of anti-measles neutralizing antibody titer, as measured by the plaque reduction neutralization test (PRNT).</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The measles per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid measles serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show measles seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate for Measles 56 Days Post-vaccination</title>
          <description>The seroconversion rate for measles at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination or a four-fold rise in concentration 56 days after vaccination if seropositive for measles at baseline. Seropositivity was defined by a concentration of ≥ 120 mIU/mL of anti-measles neutralizing antibody titer, as measured by the plaque reduction neutralization test (PRNT).</description>
          <population>The measles per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid measles serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show measles seropositivity at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="95.8" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.0" lower_limit="95.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Group 1 - Group 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate for Mumps 56 Days Post-vaccination</title>
        <description>The seroconversion rate for mumps at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination. Seropositivity was defined as an optical density ratio ≥ 1.10, measured using a commercial ELISA. Participants with equivocal serostatus at baseline are counted as non-responders.</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The mumps per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid mumps serology results at baseline and Day 56, did not take any prohibited concomitant medications within within 28 days post-vaccination, and did not show mumps seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate for Mumps 56 Days Post-vaccination</title>
          <description>The seroconversion rate for mumps at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination. Seropositivity was defined as an optical density ratio ≥ 1.10, measured using a commercial ELISA. Participants with equivocal serostatus at baseline are counted as non-responders.</description>
          <population>The mumps per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid mumps serology results at baseline and Day 56, did not take any prohibited concomitant medications within within 28 days post-vaccination, and did not show mumps seropositivity at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="93.8" upper_limit="98.5"/>
                    <measurement group_id="O2" value="95.1" lower_limit="91.8" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
            <estimate_desc>Group 1 - Group 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate for Rubella 56 Days Post-vaccination</title>
        <description>The seroconversion rate for rubella at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination or a four-fold rise in concentration 56 days after vaccination if seropositive for rubella at baseline. Seropositivity is defined as a post-vaccination concentration of ≥ 10 IU/mL measured using a commercial ELISA.</description>
        <time_frame>56 days after MMR dose 1 vaccination (Day 56)</time_frame>
        <population>The rubella per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid rubella serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show rubella seropositivity at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate for Rubella 56 Days Post-vaccination</title>
          <description>The seroconversion rate for rubella at 56 days post-vaccination was defined as the percentage of participants with a change in serostatus from negative to positive 56 days after vaccination or a four-fold rise in concentration 56 days after vaccination if seropositive for rubella at baseline. Seropositivity is defined as a post-vaccination concentration of ≥ 10 IU/mL measured using a commercial ELISA.</description>
          <population>The rubella per-protocol population included participants who fulfilled the eligibility criteria, received all study vaccines as assigned, provided valid rubella serology results at baseline and Day 56, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show rubella seropositivity at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Group 1 - Group 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Japanese Encephalitis Seropositivity 28 Days Post-vaccination</title>
        <description>Japanese encephalitis (JE) immunogenicity was assessed by the percentage of participants with demonstrated seropositivity 28 days after CD-JEV vaccination. Seropositivity was defined as an anti-JE serum neutralizing antibody titer of ≥ 1:10, as measured by JE PRNT-50.</description>
        <time_frame>28 days after CD-JEV vaccination (Day 28 for Group 1 and Day 84 for Group 2)</time_frame>
        <population>The JE per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid JE serology results at baseline and 28 days post-vaccination with CD-JEV, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show JE seropositivity at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Japanese Encephalitis Seropositivity 28 Days Post-vaccination</title>
          <description>Japanese encephalitis (JE) immunogenicity was assessed by the percentage of participants with demonstrated seropositivity 28 days after CD-JEV vaccination. Seropositivity was defined as an anti-JE serum neutralizing antibody titer of ≥ 1:10, as measured by JE PRNT-50.</description>
          <population>The JE per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid JE serology results at baseline and 28 days post-vaccination with CD-JEV, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show JE seropositivity at baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="67.0" upper_limit="77.2"/>
                    <measurement group_id="O2" value="68.2" lower_limit="62.6" upper_limit="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>11.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) for Serum Neutralizing Antibody Titer to JE Virus at 28 Days Post-vaccination</title>
        <description>Anti-JE serum neutralizing antibody titer was measured using JE PRNT-50.</description>
        <time_frame>28 days after CD-JEV vaccination (Day 28 for Group 1 and Day 84 for Group 2)</time_frame>
        <population>The JE per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid JE serology results at baseline and 28 days post-vaccination with CD-JEV, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show JE seropositivity at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for Serum Neutralizing Antibody Titer to JE Virus at 28 Days Post-vaccination</title>
          <description>Anti-JE serum neutralizing antibody titer was measured using JE PRNT-50.</description>
          <population>The JE per-protocol population included participants who fulfilled eligibility criteria, received all study vaccines as assigned, provided valid JE serology results at baseline and 28 days post-vaccination with CD-JEV, did not take any prohibited concomitant medications within 28 days post-vaccination, and did not show JE seropositivity at baseline</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="20.8" upper_limit="27.6"/>
                    <measurement group_id="O2" value="20.3" lower_limit="17.8" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Group 1 / Group 2 ratio obtained using an analysis of covariance (ANCOVA) method with log 10-transformed antibody concentration as dependent variable and treatment group as explanatory variable adjusted for log 10-transformed baseline antibody titer.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immediate Reactions Within 30 Minutes of Each Vaccination</title>
        <description>Participants were observed for 30 minutes after each vaccination for immediate reactions. Immediate reactions included both local (injection site) and systemic reactions. MMR vaccine was injected on left upper thigh and CD-JEV was injected on right upper thigh.&#xD;
Serious reactions were those meeting one of the following conditions:&#xD;
Death.&#xD;
Life threatening&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization.&#xD;
Resulted in a persistent or significant disability or incapacity.&#xD;
Important medical events that, based upon appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>30 minutes following each study vaccination</time_frame>
        <population>The safety population included all participants who received a study vaccine and had at least one safety measure post-vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR Dose 1 + CD-JEV</title>
            <description>Participants in Group 1 received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Dose 1</title>
            <description>Participants in Group 2 received one dose of MMR vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: CD-JEV</title>
            <description>Participants in Group 2 received one dose of CD-JEV on Day 56.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: MMR Dose 2</title>
            <description>Participants in Group 1 received a second dose of MMR vaccine on Day 84.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: MMR Dose 2</title>
            <description>Participants in Group 2 received a second dose of MMR vaccine on Day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Reactions Within 30 Minutes of Each Vaccination</title>
          <description>Participants were observed for 30 minutes after each vaccination for immediate reactions. Immediate reactions included both local (injection site) and systemic reactions. MMR vaccine was injected on left upper thigh and CD-JEV was injected on right upper thigh.&#xD;
Serious reactions were those meeting one of the following conditions:&#xD;
Death.&#xD;
Life threatening&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization.&#xD;
Resulted in a persistent or significant disability or incapacity.&#xD;
Important medical events that, based upon appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>The safety population included all participants who received a study vaccine and had at least one safety measure post-vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="313"/>
                <count group_id="O5" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any immediate reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="309"/>
                    <count group_id="O4" value="313"/>
                    <count group_id="O5" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR local reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="313"/>
                    <count group_id="O5" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-JEV local reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="309"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="309"/>
                    <count group_id="O4" value="313"/>
                    <count group_id="O5" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious reactions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="309"/>
                    <count group_id="O4" value="313"/>
                    <count group_id="O5" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local and Systemic Reactions Within 14 Days of Each Vaccination</title>
        <description>Reactogenicity post-vaccination was assessed from 30 minutes through 14 days following vaccination.&#xD;
Parents used a structured reactogenicity diary card to record the following solicited (pre-listed) local and system reactions.&#xD;
Local reactions (at injection site):&#xD;
Ecchymosis (bruising)&#xD;
Erythema (redness)&#xD;
Edema (swelling)&#xD;
Induration (hardness)&#xD;
Pain/tenderness&#xD;
Systemic reactions:&#xD;
Fever&#xD;
Rash&#xD;
Cough&#xD;
Runny nose&#xD;
Change in eating habits&#xD;
Diarrhea&#xD;
Sleepiness&#xD;
Irritability&#xD;
Unusual crying&#xD;
Vomiting</description>
        <time_frame>30 minutes through 14 days following each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR Dose 1 + CD-JEV</title>
            <description>Participants in Group 1 received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Dose 1</title>
            <description>Participants in Group 2 received one dose of MMR vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: CD-JEV</title>
            <description>Participants in Group 2 received one dose of CD-JEV on Day 56.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: MMR Dose 2</title>
            <description>Participants in Group 1 received a second dose of MMR vaccine on Day 84.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: MMR Dose 2</title>
            <description>Participants in Group 2 received a second dose of MMR vaccine on Day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local and Systemic Reactions Within 14 Days of Each Vaccination</title>
          <description>Reactogenicity post-vaccination was assessed from 30 minutes through 14 days following vaccination.&#xD;
Parents used a structured reactogenicity diary card to record the following solicited (pre-listed) local and system reactions.&#xD;
Local reactions (at injection site):&#xD;
Ecchymosis (bruising)&#xD;
Erythema (redness)&#xD;
Edema (swelling)&#xD;
Induration (hardness)&#xD;
Pain/tenderness&#xD;
Systemic reactions:&#xD;
Fever&#xD;
Rash&#xD;
Cough&#xD;
Runny nose&#xD;
Change in eating habits&#xD;
Diarrhea&#xD;
Sleepiness&#xD;
Irritability&#xD;
Unusual crying&#xD;
Vomiting</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="313"/>
                <count group_id="O5" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reactions at MMR injection site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="313"/>
                    <count group_id="O5" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reactions at CD-JEV injection site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="309"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic reactions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="309"/>
                    <count group_id="O4" value="313"/>
                    <count group_id="O5" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="222"/>
                    <measurement group_id="O3" value="190"/>
                    <measurement group_id="O4" value="168"/>
                    <measurement group_id="O5" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Reactions Within 14 Days of Each Vaccination by Maximum Severity</title>
        <description>Parents recorded local reactions on a diary card.&#xD;
Local ecchymosis, erythema, edema, and induration were graded as follows:&#xD;
Grade 1: ≤2.5 cm in diameter.&#xD;
Grade 2: &gt;2.5 cm in diameter with 50% of surface area of extremity segment involved.&#xD;
Grade 3: ≥50% surface area of extremity segment involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage.&#xD;
Grade 4: potentially life-threatening (e.g., abscess, exfoliative dermatitis, necrosis involving dermis or deeper tissue).&#xD;
Injection site pain/tenderness (pain without touching or tenderness when the area is touched) were graded as follows:&#xD;
Grade 1: pain/tenderness causing no or minimal limitation of use of limb. Grade 2: pain/tenderness causing greater than minimal limitation of use of limb.&#xD;
Grade 3: pain/tenderness causing inability to perform usual social and functional activities.&#xD;
Grade 4: pain/tenderness causing inability to perform basic self-care OR hospitalization indicated.</description>
        <time_frame>30 minutes through 14 days following each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR Dose 1</title>
            <description>Participants in Group 1 received one dose of MMR vaccine injected on the left upper thigh on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: CD-JEV</title>
            <description>Participants in Group 1 received one dose of CD-JEV vaccine injected on the right upper thigh on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: MMR Dose 1</title>
            <description>Participants in Group 2 received one dose of MMR vaccine injected on the left upper thigh on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: CD-JEV</title>
            <description>Participants in Group 2 received one dose of CD-JEV vaccine injected on the left upper thigh on Day 56.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: MMR Dose 2</title>
            <description>Participants in Group 1 received a 2nd dose of MMR vaccine injected on the left upper thigh on Day 84.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: MMR Dose 2</title>
            <description>Participants in Group 2 received a 2nd dose of MMR vaccine injected on the left upper thigh on Day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Reactions Within 14 Days of Each Vaccination by Maximum Severity</title>
          <description>Parents recorded local reactions on a diary card.&#xD;
Local ecchymosis, erythema, edema, and induration were graded as follows:&#xD;
Grade 1: ≤2.5 cm in diameter.&#xD;
Grade 2: &gt;2.5 cm in diameter with 50% of surface area of extremity segment involved.&#xD;
Grade 3: ≥50% surface area of extremity segment involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage.&#xD;
Grade 4: potentially life-threatening (e.g., abscess, exfoliative dermatitis, necrosis involving dermis or deeper tissue).&#xD;
Injection site pain/tenderness (pain without touching or tenderness when the area is touched) were graded as follows:&#xD;
Grade 1: pain/tenderness causing no or minimal limitation of use of limb. Grade 2: pain/tenderness causing greater than minimal limitation of use of limb.&#xD;
Grade 3: pain/tenderness causing inability to perform usual social and functional activities.&#xD;
Grade 4: pain/tenderness causing inability to perform basic self-care OR hospitalization indicated.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="314"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="313"/>
                <count group_id="O6" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Tenderness: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Tenderness: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Tenderness: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Tenderness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Reactions Within 14 Days of Each Vaccination by Maximum Severity</title>
        <description>Parents recorded systemic reactions on a diary card.&#xD;
Fever was recorded and graded as follows (axillary temperature):&#xD;
Grade 1: 37.5°C to 37.9°C&#xD;
Grade 2: 38.0°C to 38.4°C&#xD;
Grade 3: 38.5°C to 40.0°C&#xD;
Grade 4: &gt;40.0°C&#xD;
Rash, cough, runny nose, change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting, and any other unsolicited reaction occurring from 30 minutes through 14 days post vaccination were graded as follows:&#xD;
Grade 1: symptoms causing no or minimal interference with usual social and functional activities.&#xD;
Grade 2: symptoms causing greater than minimal interference with usual social and functional activities.&#xD;
Grade 3: symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.&#xD;
Grade 4: symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
        <time_frame>30 minutes through 14 days following each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR Dose 1 + CD-JEV</title>
            <description>Participants in Group 1 received one dose of MMR vaccine and one dose of CD-JEV concurrently on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Dose 1</title>
            <description>Participants in Group 2 received one dose of MMR vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: CD-JEV</title>
            <description>Participants in Group 2 received one dose of CD-JEV vaccine on Day 56.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: MMR Dose 2</title>
            <description>Participants in Group 1 received a second dose of MMR vaccine on Day 84.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: MMR Dose 2</title>
            <description>Participants in Group 2 received a second dose of MMR vaccine on Day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Reactions Within 14 Days of Each Vaccination by Maximum Severity</title>
          <description>Parents recorded systemic reactions on a diary card.&#xD;
Fever was recorded and graded as follows (axillary temperature):&#xD;
Grade 1: 37.5°C to 37.9°C&#xD;
Grade 2: 38.0°C to 38.4°C&#xD;
Grade 3: 38.5°C to 40.0°C&#xD;
Grade 4: &gt;40.0°C&#xD;
Rash, cough, runny nose, change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting, and any other unsolicited reaction occurring from 30 minutes through 14 days post vaccination were graded as follows:&#xD;
Grade 1: symptoms causing no or minimal interference with usual social and functional activities.&#xD;
Grade 2: symptoms causing greater than minimal interference with usual social and functional activities.&#xD;
Grade 3: symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.&#xD;
Grade 4: symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="313"/>
                <count group_id="O5" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="111"/>
                    <measurement group_id="O5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="143"/>
                    <measurement group_id="O4" value="133"/>
                    <measurement group_id="O5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="117"/>
                    <measurement group_id="O5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Adverse Events Within 28 Days of Each Vaccination</title>
        <description>Each adverse event (AE) was assessed for relationship to vaccine by the study clinician according to the following:&#xD;
Definitely Related: An adverse event or unanticipated problem clearly related to the research procedures.&#xD;
Possibly Related: There is a reasonable possibility that the adverse event or unanticipated problem, incident, experience, or outcome may have been caused by the procedures involved in the research.&#xD;
Not Related: Any adverse event or unanticipated problem clearly not related to study procedures.&#xD;
Related adverse events includes events that were assessed as definitely or possibly related.</description>
        <time_frame>28 days following each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR Dose 1 + CD-JEV</title>
            <description>Participants in Group 1 received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Dose 1</title>
            <description>Participants in Group 2 received one dose of MMR vaccine at Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: CD-JEV</title>
            <description>Participants in Group 2 received one dose of CD-JEV on Day 56.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: MMR Dose 2</title>
            <description>Participants in Group 1 received a second dose of MMR vaccine on Day 84.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: MMR Dose 2</title>
            <description>Participants in Group 2 received a second dose of MMR vaccine on Day 84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events Within 28 Days of Each Vaccination</title>
          <description>Each adverse event (AE) was assessed for relationship to vaccine by the study clinician according to the following:&#xD;
Definitely Related: An adverse event or unanticipated problem clearly related to the research procedures.&#xD;
Possibly Related: There is a reasonable possibility that the adverse event or unanticipated problem, incident, experience, or outcome may have been caused by the procedures involved in the research.&#xD;
Not Related: Any adverse event or unanticipated problem clearly not related to study procedures.&#xD;
Related adverse events includes events that were assessed as definitely or possibly related.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="313"/>
                <count group_id="O5" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="211"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="110"/>
                    <measurement group_id="O5" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events Throughout the Study</title>
        <description>A serious adverse event (SAE) was defined as an AE that met one of the following:&#xD;
Death&#xD;
Life threatening&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization&#xD;
Resulted in persistent or significant disability or incapacity&#xD;
Important medical events that, based upon appropriate medical judgment, jeopardized the participant and required medical or surgical intervention to prevent an outcomes listed above&#xD;
AEs were assessed for relationship to vaccine by the study clinician according to the following:&#xD;
Definitely Related: An AE or unanticipated problem clearly related to the research procedures.&#xD;
Possibly Related: There is a reasonable possibility that the AE or unanticipated problem, incident, experience, or outcome may have been caused by the procedures involved in the research.&#xD;
Not Related: Any AE or unanticipated problem clearly not related to study procedures.&#xD;
Related SAEs includes events that were assessed as definitely or possibly related.</description>
        <time_frame>Up to 112 days</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: MMR and CD-JEV</title>
            <description>Participants received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently on Day 0. Participants received a second dose of MMR per the routine immunization schedule on Day 84 (12 months of age).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: MMR Then CD-JEV</title>
            <description>Participants received one dose of MMR vaccine on Day 0 and one dose of CD-JEV 56 days later. Participants received a second dose of MMR per the routine immunization schedule on Day 84 (12 months of age).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events Throughout the Study</title>
          <description>A serious adverse event (SAE) was defined as an AE that met one of the following:&#xD;
Death&#xD;
Life threatening&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization&#xD;
Resulted in persistent or significant disability or incapacity&#xD;
Important medical events that, based upon appropriate medical judgment, jeopardized the participant and required medical or surgical intervention to prevent an outcomes listed above&#xD;
AEs were assessed for relationship to vaccine by the study clinician according to the following:&#xD;
Definitely Related: An AE or unanticipated problem clearly related to the research procedures.&#xD;
Possibly Related: There is a reasonable possibility that the AE or unanticipated problem, incident, experience, or outcome may have been caused by the procedures involved in the research.&#xD;
Not Related: Any AE or unanticipated problem clearly not related to study procedures.&#xD;
Related SAEs includes events that were assessed as definitely or possibly related.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mortality and serious adverse events were collected through the end of study, up to 112 days. Non-serious adverse events were collected through 28 days after each vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: MMR Dose 1 + CD-JEV</title>
          <description>Participants in Group 1 received one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: MMR Dose 1</title>
          <description>Participants in Group 2 received one dose of MMR vaccine at Day 0.</description>
        </group>
        <group group_id="E3">
          <title>Group 2: CD-JEV</title>
          <description>Participants in Group 2 received one dose of CD-JEV on Day 56.</description>
        </group>
        <group group_id="E4">
          <title>Group 1: MMR Dose 2</title>
          <description>Participants in Group 1 received a second dose of MMR vaccine on Day 84.</description>
        </group>
        <group group_id="E5">
          <title>Group 2: MMR Dose 2</title>
          <description>Participants in Group 2 received a second dose of MMR vaccine on Day 84.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="110" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="147" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Bullous impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Ludwig angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores, MD</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

